Indivior PLC (INDV)
Indivior PLC (NASDAQ: INDV) is a healthcare company focused on pharmaceuticals for opioid dependence and related disorders. The company develops, manufactures, and sells buprenorphine-based prescription medicines in the United States, Europe, Canada, Australia, and other international markets. Its marketed products include SUBLOCADE, a monthly extended-release injection, and SUBOXONE Film, a buprenorphine and naloxone sublingual film. Indivior also produces SUBOXONE Tablet and SUBUTEX Tablet for opioid use disorder. Beyond its commercial portfolio, the company is advancing INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 testing for moderate to severe OUD, and INDV-6001, a long-acting injectable candidate being developed with Alar Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INDV
|
$43.65
|
10.3% Upside
|
Fair
|
$50.83
|
28.5% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
19.2x
|
-33.5x
|
3.7x
|
4.77 B
|
5.161 B
|
9.6%
|
92.7%
|
4.1
|
—
|
-76.2%
|
